CRINETICS PHARMACEUTICALS IN (CRNX)
US22663K1079 - Common Stock
CRNX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While CRNX has a great health rating, there are worries on its profitability. CRNX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRNX has reported negative net income.
In the past year CRNX has reported a negative cash flow from operations.
CRNX had negative earnings in each of the past 5 years.
In the past 5 years CRNX always reported negative operating cash flow.
1.2 Ratios
CRNX has a Return On Assets of -33.77%. This is in the better half of the industry: CRNX outperforms 67.75% of its industry peers.
The Return On Equity of CRNX (-39.79%) is better than 74.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.77% | ||
| ROE | -39.79% | ||
| ROIC | N/A |
ROA(3y)-36.99%
ROA(5y)-37.98%
ROE(3y)-41.35%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRNX has more shares outstanding
The number of shares outstanding for CRNX has been increased compared to 5 years ago.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 19.70 indicates that CRNX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.70, CRNX belongs to the top of the industry, outperforming 93.00% of the companies in the same industry.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.7 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
CRNX has a Current Ratio of 13.07. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
CRNX's Current ratio of 13.07 is amongst the best of the industry. CRNX outperforms 86.86% of its industry peers.
CRNX has a Quick Ratio of 13.07. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.07, CRNX belongs to the top of the industry, outperforming 87.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.07 | ||
| Quick Ratio | 13.07 |
3. Growth
3.1 Past
The earnings per share for CRNX have decreased strongly by -17.83% in the last year.
The Revenue for CRNX has decreased by -15.19% in the past year. This is quite bad
The Revenue has been growing by 10.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-7.14%
Revenue 1Y (TTM)-15.19%
Revenue growth 3Y285.59%
Revenue growth 5Y10.55%
Revenue growth Q2Q-100%
3.2 Future
The Earnings Per Share is expected to grow by 25.97% on average over the next years. This is a very strong growth
CRNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 190.78% yearly.
EPS Next Y9.24%
EPS Next 2Y1.25%
EPS Next 3Y0.36%
EPS Next 5Y25.97%
Revenue Next Year-50.29%
Revenue Next 2Y145.85%
Revenue Next 3Y173.26%
Revenue Next 5Y190.78%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
Also next year CRNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.25%
EPS Next 3Y0.36%
5. Dividend
5.1 Amount
CRNX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CRINETICS PHARMACEUTICALS IN
NASDAQ:CRNX (5/1/2024, 7:00:01 PM)
After market: 45.05 0 (0%)45.05
+1.23 (+2.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.51B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.77% | ||
| ROE | -39.79% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.07 | ||
| Quick Ratio | 13.07 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-17.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.19%
Revenue growth 3Y285.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y